- Tytuł:
- Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
- Autorzy:
- Źródło:
- In The Lancet Respiratory Medicine March 2021 9(3):305-314
- Czasopismo naukowe